150 related articles for article (PubMed ID: 29743720)
1. Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.
Guo Y; Yang H; Chen S; Zhang P; Li R; Nimer SD; Harbour JW; Xu M; Yang FC
Leukemia; 2018 Aug; 32(8):1834-1837. PubMed ID: 29743720
[No Abstract] [Full Text] [Related]
2. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
[TBL] [Abstract][Full Text] [Related]
4. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
[TBL] [Abstract][Full Text] [Related]
6. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
[TBL] [Abstract][Full Text] [Related]
7. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of tumor suppressive ASXL1-PTEN/AKT axis in myeloid malignancies.
Cao L; Xia X; Kong Y; Jia F; Yuan B; Li R; Li Q; Wang Y; Cui M; Dai Z; Zheng H; Christensen J; Zhou Y; Wu X
J Mol Cell Biol; 2020 Sep; 12(9):688-699. PubMed ID: 32236560
[TBL] [Abstract][Full Text] [Related]
10. [Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia].
Asada S
Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
[TBL] [Abstract][Full Text] [Related]
11. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
[TBL] [Abstract][Full Text] [Related]
12. Loss of the tumor suppressor BAP1 causes myeloid transformation.
Dey A; Seshasayee D; Noubade R; French DM; Liu J; Chaurushiya MS; Kirkpatrick DS; Pham VC; Lill JR; Bakalarski CE; Wu J; Phu L; Katavolos P; LaFave LM; Abdel-Wahab O; Modrusan Z; Seshagiri S; Dong K; Lin Z; Balazs M; Suriben R; Newton K; Hymowitz S; Garcia-Manero G; Martin F; Levine RL; Dixit VM
Science; 2012 Sep; 337(6101):1541-6. PubMed ID: 22878500
[TBL] [Abstract][Full Text] [Related]
13. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
[TBL] [Abstract][Full Text] [Related]
14. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
Zhang P; He F; Bai J; Yamamoto S; Chen S; Zhang L; Sheng M; Zhang L; Guo Y; Man N; Yang H; Wang S; Cheng T; Nimer SD; Zhou Y; Xu M; Wang QF; Yang FC
J Clin Invest; 2018 Dec; 128(12):5383-5398. PubMed ID: 30226831
[TBL] [Abstract][Full Text] [Related]
15. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
[TBL] [Abstract][Full Text] [Related]
16. Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers.
Elyamany G; Akhter A; Kamran H; Rizwan H; Shabani-Rad MT; Alkhayat N; Al Sharif O; Elborai Y; Al Shahrani M; Mansoor A
Pediatr Hematol Oncol; 2021 Sep; 38(6):581-592. PubMed ID: 33764257
[TBL] [Abstract][Full Text] [Related]
17. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
18. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.
Wu X; Bekker-Jensen IH; Christensen J; Rasmussen KD; Sidoli S; Qi Y; Kong Y; Wang X; Cui Y; Xiao Z; Xu G; Williams K; Rappsilber J; Sønderby CK; Winther O; Jensen ON; Helin K
Cell Res; 2015 Nov; 25(11):1205-18. PubMed ID: 26470845
[TBL] [Abstract][Full Text] [Related]
20. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
[No Abstract] [Full Text] [Related]
[Next] [New Search]
